13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
39 檔
25.2%
During the Q4 2024 filing period, Acuta Capital Partners, LLC (CIK: 0001582844) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $143.5M across 39 reported positions.
Acuta Capital Partners, LLC executed strategic sector rebalancing during Q4 2024, establishing 8 new positions while fully exiting 10 holdings and trimming 15 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCUL | Ocular Therapeutix Inc | Stock-Other | 9.55% | +0.07% | -6.64% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 7.28% | — | -2.51% | |
| 3 | TRML | Tourmaline Bio Inc | Stock-Other | 7.18% | — | +5.95% | |
| 4 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 6.32% | — | -6.68% | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.05% | — | -9.79% | |
| 6 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 5.87% | +6.59% | — | |
| 7 | PRAX | Praxis Precision Medicines I | Stock-Other | 5.23% | -0.13% | +17.39% | |
| 8 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 4.92% | -1.80% | EXIT | |
| 9 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.28% | +0.60% | +17.12% | |
| 10 | PCVX | Vaxcyte Inc | Stock-Other | 3.71% | — | -66.77% | |
| 11 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.20% | — | +165.73% | |
| 12 | ASND | Ascendis Pharma A/S | Stock-Other | 3.18% | — | +9.41% | |
| 13 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 2.74% | — | -38.18% | |
| 14 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 2.50% | -1.27% | — | |
| 15 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.49% | -18.59% | EXIT | |
| 16 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.35% | — | +39.14% | |
| 17 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.91% | — | — | |
| 18 | ✓ | Stock-Other | 1.84% | — | +16.36% | ||
| 19 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.70% | — | -29.21% | |
| 20 | LQDA | Liquidia CORP | Stock-Other | 1.63% | — | +87.36% | |
| 21 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.61% | — | -6.63% | |
| 22 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.54% | +1.27% | -58.27% | |
| 23 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.53% | — | +140.93% | |
| 24 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.47% | — | — | |
| 25 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.29% | — | — | |
| 26 | ZYME | Zymeworks Inc | Stock-Other | 0.99% | — | — | |
| 27 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.98% | — | — | |
| 28 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.91% | — | +9.65% | |
| 29 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.89% | — | -16.33% | |
| 30 | GILD | Gilead Sciences Inc | Stock-Healthcare | 0.85% | — | -53.08% | |
| 31 | ACLXGBX | Arcellx Inc | Stock-Other | 0.83% | — | -82.70% | |
| 32 | SGMOQ | Sangamo Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 33 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.52% | — | +221.12% | |
| 34 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.45% | +1.76% | NEW | |
| 35 | FBRX | Forte Biosciences Inc | Stock-Other | 0.41% | — | — | |
| 36 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.40% | — | — | |
| 37 | CELC | Celcuity Inc | Stock-Other | 0.33% | — | -46.35% | |
| 38 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.29% | — | -6.82% | |
| 39 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | WHWK | Whitehawk Therapeutics Inc | +2.8% | — | Unchanged |
| 2 | PRAX | Praxis Precision Medicines I | +2.6% | +17.39% | Add |
| 3 | DRUG | Bright Minds Biosciences Inc | +2.5% | NEW | New buy |
| 4 | TRVI | Trevi Therapeutics Inc | +2.4% | +165.73% | Add |
| 5 | ARGX | Argenx Se - Adr | +1.7% | +17.12% | Add |
| 6 | CDTX | Cidara Therapeutics Inc | +1.5% | NEW | New buy |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | +1.3% | NEW | New buy |
| 8 | TECX | Tectonic Therapeutic Inc | +1.2% | +140.93% | Add |
| 9 | ✓ | +1.2% | +16.36% | Add | |
| 10 | OCUL | Ocular Therapeutix Inc | +1.2% | -6.64% | Trim |
| 11 | LQDA | Liquidia CORP | +1% | +87.36% | Add |
| 12 | ZYME | Zymeworks Inc | +1% | NEW | New buy |
| 13 | EWTX | Edgewise Therapeutics Inc | +1% | +39.14% | Add |
| 14 | ELDN | Eledon Pharmaceuticals Inc | +1% | NEW | New buy |
| 15 | RVMD | Revolution Medicines Inc | +1% | +3.43% | Add |
| 16 | INSM | Insmed Inc | +0.9% | -2.51% | Trim |
| 17 | CRNX | Crinetics Pharmaceuticals In | +0.9% | -6.68% | Trim |
| 18 | SGMOQ | Sangamo Therapeutics Inc | +0.8% | NEW | New buy |
| 19 | ASND | Ascendis Pharma A/S | +0.6% | +9.41% | Add |
| 20 | FBRX | Forte Biosciences Inc | +0.4% | NEW | New buy |
| 21 | CRVS | Corvus Pharmaceuticals Inc | +0.4% | NEW | New buy |
| 22 | ✓ | Helix Acquisition CORP Ii | +0.4% | — | Unchanged |
| 23 | ✓ | Third Harmonic Bio Inc | +0.4% | +221.12% | Add |
| 24 | ✓ | Verve Therapeutics Inc | +0.3% | +9.65% | Add |
| 25 | TRML | Tourmaline Bio Inc | +0.3% | +5.95% | Add |
| 26 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 27 | RAPP | Rapport Therapeutics Inc | — | -6.82% | Trim |
| 28 | ELVN | Enliven Therapeutics Inc | -0.1% | -9.79% | Trim |
| 29 | ARTV | Artiva Biotherapeutics Inc | -0.1% | — | Unchanged |
| 30 | CLYM | Climb Bio Inc | -0.2% | EXIT | Sold out |
| 31 | BNTC | Benitec Biopharma Inc | -0.2% | EXIT | Sold out |
| 32 | TVTX | Travere Therapeutics Inc | -0.2% | EXIT | Sold out |
| 33 | ✓ | Mersana Therapeutics Inc | -0.2% | -6.63% | Trim |
| 34 | CELC | Celcuity Inc | -0.2% | -46.35% | Trim |
| 35 | RARE | Ultragenyx Pharmaceutical In | -0.2% | -16.33% | Trim |
| 36 | CYPH | Cypherpunk Technologies Inc | -0.3% | EXIT | Sold out |
| 37 | CRBP | Corbus Pharmaceuticals Holdi | -0.3% | EXIT | Sold out |
| 38 | GILD | Gilead Sciences Inc | -0.5% | -53.08% | Trim |
| 39 | GERN | Geron CORP | -0.6% | EXIT | Sold out |
| 40 | 430 | Terns Pharmaceuticals Inc | -0.8% | -8.11% | Trim |
| 41 | RCKT | Rocket Pharmaceuticals Inc | -1.1% | -29.21% | Trim |
| 42 | DYN | Dyne Therapeutics Inc | -1.3% | EXIT | Sold out |
| 43 | ✓ | Acelyrin Inc | -1.5% | EXIT | Sold out |
| 44 | MREO | Mereo Biopharma Group Pl-adr | -1.5% | -38.18% | Trim |
| 45 | TSHA | Taysha Gene Therapies Inc | -1.9% | -58.27% | Trim |
| 46 | CMPS | Compass Pathways PLC | -2% | EXIT | Sold out |
| 47 | KURA | Kura Oncology Inc | -3.1% | EXIT | Sold out |
| 48 | ACLXGBX | Arcellx Inc | -3.4% | -82.70% | Trim |
| 49 | PCVX | Vaxcyte Inc | -8.8% | -66.77% | Trim |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 39 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCUL, INSM, TRML) accounted for 25.2% of total reported equity market value during Q4 2024.
Top New Position Initiated
DRUG
市值: $2.5M
Top Position Liquidated / Trimmed
KURA
前期市值: $3.8M
During Q4 2024, Acuta Capital Partners, LLC's top holdings by market value included OCUL (9.6%)、INSM (7.3%)、TRML (7.2%). The largest single position, OCUL, represented 9.6% of total portfolio value.
In Q4 2024, Acuta Capital Partners, LLC made 45 total portfolio adjustments, initiating 8 new buys, adding to 12 positions, trimming 15 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.